The biggest US drug-benefits manager is making a move that will take a bite out of sales for one of the world’s top-selling medications.
Starting April 1, CVS Health Corp. will no longer offer AbbVie Inc.’s Humira to most of the millions of patients in its commercial prescription plans. Instead, they’ll be directed to cheaper copycats of the anti-inflammatory drug that became available last year.
ncG1vNJzZmivp6x7o7jOqKSbnaKce6S7zGilnq%2BjZK6zwMico56rX2d9c4CMaWhmaGNksLe%2FjK2mZqqVpbmir8RmmJuapp6ybr%2BMm6Oom5uXwrTAxKtkoa2dnr%2Biedaiq6Flk52yorzEq2SroaaWubQ%3D